For example, notable cysteine-reactive covalent drugs such as ibrutinib and acalabrutinib have transformed cancer therapy by selectively inhibiting Bruton’s tyrosine kinase (BTK) through a covalent mechanism, with minimal off-target effects on other kinases. This evidence concerns the gene BTK and cancer.